Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023)

Historic EBITDA Margin for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to 9477.68%.

  • Gain Therapeutics' EBITDA Margin fell 21709300.0% to 9477.68% in Q1 2023 from the same period last year, while for Dec 2023 it was 40328.26%, marking a year-over-year decrease of 276401600.0%. This contributed to the annual value of 40328.26% for FY2023, which is 276401600.0% down from last year.
  • According to the latest figures from Q1 2023, Gain Therapeutics' EBITDA Margin is 9477.68%, which was down 21709300.0% from 5442.98% recorded in Q2 2022.
  • Gain Therapeutics' EBITDA Margin's 5-year high stood at 3941.29% during Q2 2021, with a 5-year trough of 46819.42% in Q1 2021.
  • For the 4-year period, Gain Therapeutics' EBITDA Margin averaged around 13028.23%, with its median value being 8355.01% (2020).
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -391428100bps in 2021, then soared by 395126600bps in 2022.
  • Over the past 4 years, Gain Therapeutics' EBITDA Margin (Quarter) stood at 17678.47% in 2020, then soared by 58bps to 7426.33% in 2021, then increased by 27bps to 5442.98% in 2022, then crashed by -74bps to 9477.68% in 2023.
  • Its last three reported values are 9477.68% in Q1 2023, 5442.98% for Q2 2022, and 7306.75% during Q1 2022.